SpringWorks Therapeutics, Inc.
SWTXNASDAQHealthcare
$46.99
+$0.01(+0.02%)
Market Cap$3.5B
P/E Ratio—
52W High$62
52W Low$28.21
SpringWorks Therapeutics, Inc. (SWTX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · SWTX · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.19B | $0.01B | $0.01B | $0.00B | $0.04B |
| Cost of Revenue | $0.01B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.18B | $0.01B | $0.00B | ($0.00B) | $0.03B |
| Gross Margin %(computed) | 93.45% | 92.25% | 69.16% | — | 99.00% |
| Operating Expenses | |||||
| R&D Expenses | $0.20B | $0.15B | $0.15B | $0.10B | $0.05B |
| G&A Expenses | $0.26B | $0.20B | $0.13B | $0.07B | $0.03B |
| Total Operating Expenses | $0.46B | $0.35B | $0.28B | $0.17B | $0.08B |
| Operating Income | ($0.28B) | ($0.34B) | ($0.28B) | ($0.17B) | ($0.05B) |
| Operating Margin %(computed) | -145.17% | — | — | — | -132.35% |
| Interest Income | $0.03B | $0.02B | $0.01B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.26B) | ($0.33B) | ($0.28B) | ($0.17B) | ($0.05B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.26B) | ($0.33B) | ($0.28B) | ($0.17B) | ($0.05B) |
| Net Margin %(computed) | -134.73% | — | — | — | -130.21% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-3.48 | $-5.15 | $-5.21 | $-3.59 | $-1.05 |
| Wtd Avg Shares | 0.07B | 0.06B | 0.05B | 0.05B | 0.04B |
| EBITDA | ($0.27B) | ($0.34B) | ($0.28B) | ($0.17B) | ($0.05B) |
| EBITDA Margin %(computed) | -143.36% | — | — | — | -131.36% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more SpringWorks Therapeutics, Inc. data
About SpringWorks Therapeutics, Inc. (SWTX) Income Statement
SpringWorks Therapeutics, Inc. (SWTX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2024, SWTX reported revenue of $0.19B, gross profit of $0.18B (gross margin 93.45%), and net income of ($0.26B) — a net profit margin of -134.73%.
Frequently asked questions
SWTX · 4 questionsSpringWorks Therapeutics, Inc. (SWTX) reported revenue of $0.19B for 2024, up 3417.3% year-over-year.
SWTX revenueSWTX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09